|
Dear All,
Greetings from the IRA E-Newsletter Editorial Team.
A few practically relevant studies are the highlight of this issue.
The first one is hydroxychoroquine use in rheumatoid arthritis (J Am Heart Assoc. 2016 Jan) decreases cardiovascular events by 72%. This if the first of its kind (published report), although we do know from previous studies that it has favorable metabolic effects.
Another study shows that asymptomatic lung disease is very common in early RA patients (45% subclinical lung disease by HRCT or PFT in the study reported here). This is important information but needs to be confirmed from larger cohorts. The study is published is Chron Respir Dis. 2016 Feb.
In yet another study (Arthritis Care Res Feb 2016), investigators have reported radiographic sacroiliitis on MRI in juvenile ankylosing spondylitis patients without low back pain. More studies are needed to validate this.
Finally, there is a report on higher methotrexate intolerance and behavioral abnormalities with subcutaneous methotrxate (the preferred route, especially in children) than oral methotrexate in juvenile idiopathic arthritis. This study is published is Clin Exp Rheumatol. 2016 Feb 2.
‘The perspective’ reminds us to listen to our patients.
We welcome your suggestions. Please send your suggestions/comments to:
iraenewsletter@hotmail.com
Website: www.iraenewsletter.com
Regards,
Banwari Sharma
Editor, IRA e-Newsletter
|
|
